CD8A and neoplasm: Antibody-mediated depletion of CD8+ T cells was confirmed by flow cytometry whereby CD8+ T cells comprised < 2% of circulating CD3+ T cells compared to >18% in the isotype control antibody-treated group at the time-point when lungs were analyzed for tumor burden (i.e., 30 days after primary tumor implantation; S3 Fig).